Predicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

This study was initiated to identify clinical and dietary parameters that predict efficacy of dipeptidyl peptidase‐4 inhibitors. A total of 72 untreated Japanese patients with type 2 diabetes who received DPP‐4 inhibitors (sitagliptin, alogliptin or vildagliptin) for 4 months were examined for chang...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes investigation 2012-10, Vol.3 (5), p.464-467
Main Authors: Iwasaki, Masahiro, Hoshian, Fuminori, Tsuji, Tomoko, Hirose, Naoki, Matsumoto, Tomoko, Kitatani, Naomi, Sugawara, Kenji, Usui, Ryota, Kuwata, Hitoshi, Sugizaki, Kazu, Kitamoto, Yuka, Fujiwara, Shuichi, Watanabe, Koin, Hyo, Takanori, Kurose, Takeshi, Seino, Yutaka, Yabe, Daisuke
Format: Article
Language:English
Subjects:
Dipeptidyl peptidase‐4 inhibitor
n‐3 Polyunsaturated fatty acid
Short Report
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study was initiated to identify clinical and dietary parameters that predict efficacy of dipeptidyl peptidase‐4 inhibitors. A total of 72 untreated Japanese patients with type 2 diabetes who received DPP‐4 inhibitors (sitagliptin, alogliptin or vildagliptin) for 4 months were examined for changes of glycated hemoglobin (HbA1c) and body mass index (BMI), and self‐administered 3‐day food records, as well as serum levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). DPP‐4 inhibitors significantly reduced HbA1c (before initiation of DPP‐4 inhibitors 7.2 ± 0.7%, 4 months after initiation of DPP‐4 inhibitors 6.7 ± 0.6% [paired t‐test, P 
ISSN:2040-1116
2040-1124
DOI:10.1111/j.2040-1124.2012.00214.x